CompletedPhase 2

Measuring Blood Flow in the Brain After Epileptic Activity

Netherlands34 participantsStarted 2019-12-05

Plain-language summary

In this clinical trial, postictal phenomena (i.e., headache, delirium) will be investigated after administration of acetaminophen and nimodipine in depressed patients receiving electroconvulsive therapy (ECT). Postictal phenomena are thought to result from decreased cerebral blood flow and decreased oxygen concentration in the brain. It is expected that acetaminophen and nimodipine will reduce these postictal phenomena, compared to no treatment, because they target these mechanisms.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adulthood (age \> 17 years); * Current clinical diagnosis of depressive episode (unipolar, bipolar, schizoaffective); * Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements. Exclusion Criteria: * Known adverse or allergic reactions to acetaminophen or nimodipine; * Chronic use of acetaminophen, calcium-antagonists or NSAID's that cannot be interrupted for less than two days before the ECT-session;

What they're measuring

Time to EEG normalization

Timeframe: Change from ictal to baseline EEG activity, up to 12 times per patient (across 6 weeks)

Trial details

NCT IDNCT04028596

SponsorRijnstate Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-30

View on ClinicalTrials.gov More Epilepsy trials